Tier 1 — highest

Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review

Peter Calverley, Paola Rogliani, Alberto Papi
Drug Saf 2021 44(3):273-290

Bibliography

PubMed
PMID 33326056
PubMed Central
PMC7892733
DOI
10.1007/s40264-020-01026-y
Funding
Funding disclosure was not located in the indexed record reviewed; consult the source publication for the full funding statement.
Competing interests
Competing-interest disclosure was not located in the indexed record reviewed; consult the source publication for the full declaration.

Study snapshot

DesignSystematic safety review
ModelHuman
Sample41 articles using 600-3,000 mg/day
InterventionMostly oral NAC across chronic respiratory diseases
DurationVaried chronic-treatment periods
EndpointsAdverse events; Gastrointestinal symptoms; Dose-related safety

What the study showed, in plain terms

Focused review of chronic NAC safety at doses up to 3 g/day in respiratory populations.

Key findings

Oral high-dose NAC generally showed a safety profile similar to standard dosing, with gastrointestinal symptoms the main practical issue.

What this study can and cannot tell us

Disease-specific safety literature; review had extensive author-industry relationships and one sponsor relationship disclosed.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology